Hims & Hers Health, Inc. (HIMS) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing telehealth consultations, prescription fulfillment, and wellness products. The company serves customers in the United States, United Kingdom, Canada, and the European Union. In 2025, the company expanded its international footprint through the acquisitions of Zava (UK/EU) and Medici (Canada) and launched comprehensive laboratory testing services.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $2,347.6 million | $1,476.5 million | +59% |
| Net Income | $128.4 million | $126.0 million | +2% |
| Adjusted EBITDA | $318.0 million | $176.9 million | +80% |
| Adjusted EBITDA Margin | 14% | 12% | +200 bps |
| Gross Margin | 74% | 79% | -500 bps |
| Free Cash Flow | $57.4 million | $198.3 million | -71% |
| Subscribers (End of Period) | 2.51 million | 2.23 million | +13% |
| Cash & Investments | $928.8 million | $300.3 million | N/A |
Note: Free Cash Flow decreased primarily due to significant capital expenditures ($226.0 million) for internal fulfillment capabilities and investments in available-for-sale securities.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 53% increase in U.S. revenue and a 399% surge in "Rest of the World" revenue due to new international acquisitions. Personalized offerings (including compounded GLP-1s) now represent over 70% of U.S. revenue.
- Margin Compression: Gross margin declined from 79% to 74%, attributed to higher product and shipping costs associated with weight loss offerings and the growth of international operations.
- Acquisitions: Completed acquisitions of Zava (July 2025) and Medici (November 2025), and an asset acquisition of C S Bio Co. (February 2025) to strengthen supply chain capabilities.
- Capital Structure: Issued $1.0 billion in 0% convertible senior notes due 2030 in May 2025, netting approximately $968.7 million in proceeds.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management expects continued investment in growth, including expansion of internal fulfillment, marketing, and new product offerings. The company plans to expand into Australia and Japan via the proposed acquisition of Eucalyptus (announced February 2026, expected to close mid-2026).
Regulatory Risks (Critical):
- FDA Actions: In February 2026, the FDA issued a statement indicating an intent to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs, directly naming Hims & Hers. The company received warning letters in September 2025 regarding compounded semaglutide promotion.
- Government Investigations: In February 2026, the HHS referred the company to the Department of Justice (DOJ) for investigation regarding potential FDCA violations. The SEC also opened an investigation in February 2026 regarding public statements on compounded semaglutide.
- Patent Litigation: Novo Nordisk filed a patent infringement lawsuit in February 2026 regarding compounded GLP-1 products containing semaglutide.
Cybersecurity Incident: In early February 2026, a social engineering attack allowed unauthorized access to customer service software. The company confirmed access to PII (names, emails, phone numbers) and treatment category data but stated the electronic medical record was not accessed. The company does not currently believe the incident will materially impact financial results.
Investor Verification Checklist
- Regulatory Exposure: Verify the potential financial and operational impact of the FDA's February 2026 statement and the DOJ/SEC investigations on the company's core GLP-1 revenue stream.
- Acquisition Integration: Assess the integration progress and financial contribution of Zava and Medici, and the terms of the proposed Eucalyptus acquisition ($1.15 billion total consideration).
- Margin Sustainability: Monitor whether gross margins stabilize as the company scales internal fulfillment and manages the cost structure of weight loss offerings.
- Liquidity Position: Confirm the sufficiency of cash reserves ($928.8 million) and credit facility availability ($168.0 million) to fund the Eucalyptus acquisition and ongoing operations amidst regulatory uncertainty.
- Legal Reserves: Review future filings for any quantification of potential losses related to the Novo Nordisk patent lawsuit and securities class actions.